Peptides Archives

News and Trends 31 Mar 2023

Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China

Ablaze Pharmaceuticals, a biotech company focused on developing targeted radiotherapy (TRT) to benefit cancer patients in China, is developing plans for a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3-targeting peptide is being licensed from RayzeBio. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and […]

March 31, 2023 - 2 minutesmins - By Jim Cornall

artificial intelligence AI drug discovery

News and Trends 9 Mar 2023

Iktos raises €15.5M to expand AI drug discovery technologies

Iktos, a company specializing in artificial intelligence (AI) for new drug discovery, has closed a €15.5 million ($16.4 million) Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. This financing will enable Iktos to further develop its AI and drug discovery capabilities and expand its existing SaaS software […]

March 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Korean researchers develop antimicrobial peptides discovery tool

Antimicrobial peptides (AMPs) are a promising new weapon for combating the growing antimicrobial resistance (AMR) of bacteria and other harmful microorganisms. Now, researchers from the Gwangju Institute of Science and Technology (GIST) in South Korea have developed a new, easy-to-interpret AI-powered AMP prediction model. The tool, named AMP-BERT, can capture the functional and structural properties […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Cytovation melanoma study under way

Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study. The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs). The study is an expansion arm […]

February 16, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

IMV presents positive lymphoma trial results

IMV Inc. has announced positive preliminary data from its VITALIZE phase 2B trial. The study is evaluating IMV Inc. lead DPX product, maveropepimut-S (MVP-S), in combination with pembrolizumab, in patients with relapsed, refractory diffuse large B cell lymphoma (r/r DLBCL). IMV Inc. is a biopharmaceutical company developing a portfolio of immune-educating therapies based on its […]

February 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

New method to design new peptide therapeutics

Researchers at Hokkaido University in Japan have developed a novel method to design and develop peptide antibiotics in large numbers, which could prove critical to controlling antibiotic resistance. Applications of new molecules as drugs are expected to be effective in treating diseases that are difficult to cure with currently used conventional drugs. Peptides are one […]

February 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Orbit Discovery and Endevica Bio to develop cachexia therapeutics

Orbit Discovery Limited has entered into a multi target research agreement with Endevica Bio Inc. Endevica creates first-in-class therapeutics for cachexia caused by cancer and other chronic conditions. Its lead compound has proven to be safe and well-tolerated in phase 1 trials. The collaboration aims to accelerate Endevica’s development of advanced G-protein coupled receptor (GPCR)-targeting […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

New tool to fight antibiotic resistance

The World Health Organization (WHO) ranks antibiotic resistance as one of the top 10 threats to global health. In response, researchers at Chalmers University of Technology in Sweden have developed a new spray that can kill antibiotic-resistant bacteria, and that can be used for wound care and directly on implants and other medical devices. “Our […]

January 26, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 6 Jan 2023

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

Orbit Discovery Limited has entered into a master service agreement with SanegeneBio Inc., a start-up company dedicated to developing novel RNAi-based medicines. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes. The agreement covers activities ranging from hit ID to cell-based […]

January 6, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Funding to develop wearable patch for type 2 diabetes

A project to develop a patch worn on the cheek that delivers peptide treatments for type 2 diabetes has been awarded just under €3.8 million ($3.9 million) by the EU’s Horizon Europe RESILIENCE program. The ‘BUCCAL-PEP’ project will combine skills to develop a multifunctional biomaterial patch which allows, for the first time, delivery of peptide […]

November 23, 2022 - 4 minutesmins - By Jim Cornall

Interview 28 Oct 2022

Migraines: a new vaccine frontier beyond infectious diseases

By bringing the efficiency and affordability of vaccines to chronic diseases such as migraines, U.S. company Vaxxinity aims to open a new frontier for vaccines in an effort to reach all patient populations, regardless of location or income. Migraine causes severe headaches that are characterized by throbbing pain and associated symptoms such as sensitivity to […]

October 28, 2022 - 7 minutesmins - By Omnia Ibrahim

News and Trends 12 Sep 2022

Enterome presents more data on therapeutic cancer treatment

Clinical stage biopharma company Enterome has presented new data from its two phase 1/2 clinical trials of its OncoMimics cancer immunotherapy EO2401. The trails are in combination with nivolumab (Opdivo) +/- bevacizumab (Avastin), in patients with first progression/recurrence of glioblastoma (ROSALIE trial), and in combination with nivolumab in patients with non-resectable adrenocortical carcinomas (ACC) and […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us